Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Metformin (Geropharm) vs Glucophage
NCT03458208Phase 1Completed
- Sponsor
- Geropharm
- Start
- Feb 2017
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Geropharm. Primary endpoints: Maximum Plasma Concentration at 26 hours and Area Under the Curve from time 0 to last measurable concentration at 26 hours. Started Feb 2017; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03458208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03458208.